Literature DB >> 18464308

The relationship between neuropsychiatric, clinical, and laboratory variables and quality of life of Chinese patients with systemic lupus erythematosus.

Lai-Shan Tam1, Adrian Wong, Vincent C T Mok, Yan-Er Zhu, Lai-Wa Kwok, Tena K Li, Kong-Chiu Wong, Edmund K Li.   

Abstract

OBJECTIVE: To investigate the role of neuropsychiatric (NP), clinical, and laboratory variables in influencing the health related quality of life (HRQOL) of Chinese patients with systemic lupus erythematosus (SLE).
METHODS: The Medical Outcomes Study Short Form-36 was applied in a cohort of 291 patients with SLE. At the time of HRQOL testing all patients underwent a clinical and laboratory evaluation together with measures of disease activity and damage. Patients also submitted to a battery of NP tests.
RESULTS: Using multivariate analysis, NP involvement-ever was associated with impairment of the general health subscale. Cerebrovascular disease and mononeuropathy were associated with impairment of the physical function subscale, while the latter was also associated with impairment of the role-emotional subscale. Cognitive impairment was associated with impairment of the mental health subscale. The Hospital Anxiety and Depression (HAD) depression score was associated with impairment of all the 8 subscales, physical, and mental summary scores. The HAD anxiety score was associated with impairment of predominantly mental function. Active arthritis, lower education level, and serum albumin levels were associated with impairment of predominantly physical function. Advancing age and damage were associated with impairment of both physical and mental function. Low hemoglobin level and female sex were associated with impairment of predominantly mental function.
CONCLUSION: NP involvement and low-grade inflammation as reflected by low serum albumin and hemoglobin concentrations were associated with impaired HRQOL in patients with SLE, independent of other sociodemographic and clinical variables.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18464308

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  15 in total

Review 1.  Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations.

Authors:  George K Bertsias; Dimitrios T Boumpas
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

2.  Anti-NR2 antibodies, blood-brain barrier, and cognitive dysfunction.

Authors:  Gaurav Gulati; Philip H Iffland; Damir Janigro; Bin Zhang; Michael E Luggen
Journal:  Clin Rheumatol       Date:  2016-06-29       Impact factor: 2.980

3.  Prevalence and risk factors of anxiety and depression in patients with systemic lupus erythematosus in Southwest China.

Authors:  Xia Xie; Dongmei Wu; Hong Chen
Journal:  Rheumatol Int       Date:  2016-08-31       Impact factor: 2.631

4.  SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus.

Authors:  J G Hanly; M B Urowitz; D Jackson; S C Bae; C Gordon; D J Wallace; A Clarke; S Bernatsky; A Vasudevan; D Isenberg; A Rahman; J Sanchez-Guerrero; J Romero-Diaz; J T Merrill; P R Fortin; D D Gladman; I N Bruce; K Steinsson; M Khamashta; G S Alarcón; B Fessler; M Petri; S Manzi; O Nived; G Sturfelt; R Ramsey-Goldman; M A Dooley; C Aranow; R Van Vollenhoven; M Ramos-Casals; A Zoma; K Kalunian; V Farewell
Journal:  Ann Rheum Dis       Date:  2011-02-21       Impact factor: 19.103

5.  Organ damage in patients with incomplete lupus syndromes: from a Chinese academic center.

Authors:  Zhen Chen; Meng-Tao Li; Dong Xu; Xiao-Mei Leng; Qian Wang; Xin-Ping Tian; Shang-Zhu Zhang; Yan Zhao; Xiao-Feng Zeng
Journal:  Clin Rheumatol       Date:  2015-02-18       Impact factor: 2.980

Review 6.  Pitfalls and opportunities in measuring patient outcomes in lupus.

Authors:  Meenakshi Jolly
Journal:  Curr Rheumatol Rep       Date:  2010-08       Impact factor: 4.592

7.  Damage accrual, cumulative glucocorticoid dose and depression predict anxiety in patients with systemic lupus erythematosus.

Authors:  Anselm Mak; Catherine So-Kum Tang; Moon-Fai Chan; Alicia Ai-Cia Cheak; Roger Chun-Man Ho
Journal:  Clin Rheumatol       Date:  2011-01-11       Impact factor: 2.980

8.  Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus.

Authors:  J G Hanly; M B Urowitz; L Su; S C Bae; C Gordon; D J Wallace; A Clarke; S Bernatsky; D Isenberg; A Rahman; G S Alarcón; D D Gladman; P R Fortin; J Sanchez-Guerrero; J Romero-Diaz; J T Merrill; E Ginzler; I N Bruce; K Steinsson; M Khamashta; M Petri; S Manzi; M A Dooley; R Ramsey-Goldman; R Van Vollenhoven; O Nived; G Sturfelt; C Aranow; K Kalunian; M Ramos-Casals; A Zoma; J Douglas; K Thompson; V Farewell
Journal:  Ann Rheum Dis       Date:  2009-04-08       Impact factor: 19.103

Review 9.  The socioeconomic burden of SLE.

Authors:  Chak Sing Lau; Anselm Mak
Journal:  Nat Rev Rheumatol       Date:  2009-06-09       Impact factor: 20.543

10.  Non-criteria anti-phospholipid antibodies and cognitive impairment in SLE.

Authors:  Michael E Luggen; Gaurav Gulati; Bin Zhang; Rohan A Willis; Emilio B Gonzalez
Journal:  Clin Rheumatol       Date:  2015-11-12       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.